OKYO Pharma Reports Filing Of An Investigational New Drug (IND) Application For OK-101 To Treat Neuropathic Corneal Pain
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma has filed an Investigational New Drug (IND) application for OK-101, aimed at treating neuropathic corneal pain. The company plans to start enrolling for the study in Q1 2024, pending FDA approval.
October 09, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
OKYO Pharma's filing of an IND application for OK-101 could potentially open a new revenue stream if approved. However, the impact is likely to be felt in the long term, as study enrollment is planned for Q1 2024.
The filing of an IND application is a significant step for OKYO Pharma, indicating progress in their product pipeline. However, the impact on the company's stock price is likely to be neutral in the short term, as the study enrollment is planned for Q1 2024 and is subject to FDA approval. If approved, this could potentially open a new revenue stream for the company, but this is a long-term prospect.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100